ClinicalTrials.gg
CompletedNCT06250205Updated Sep 19, 2024

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

A Phase 1 interventional study of Obicetrapib and Obicetrapib + Drospirenone / Ethinyl Estradiol (COC) in Healthy Volunteers, sponsored by NewAmsterdam Pharma. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by NewAmsterdam Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.

Read the detailed description

This is an interventional, drug-drug interaction study to evaluate the effect of daily doses of Obicetrapib tablets on the pharmacokinetics of a combined oral contraceptive (COC), Drospirenone and Ethinyl Estradiol.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • DDI, drug-drug interaction, combined oral contraceptive
03

In context

Lead sponsor

NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-pregnant, non-lactating, non-tobacco-, non-nicotine-using female, 18-35 years of age, inclusive, who is a candidate for hormonal (as determined by the Investigator).
  • Subject has a of 18.5-29.9 kg/m², inclusive. BMI will be calculated using Novum Pharmaceutical Research Services Standard Operating Procedures.
  • If the subject is currently using a hormonal method of contraception, the subject is willing and agrees to stop using her hormonal contraceptive throughout the duration of the study and is prepared to abstain from sexual intercourse or use a reliable non-hormonal method of contraception, as outlined below

Exclusion criteria

Exclusion Criteria:

  • Male
  • Have given birth or been pregnant within 3 months before initial dosing, or is currently pregnant, lactating or likely to become pregnant during the study.
  • History of Hypertension, or seated blood pressure for a minimum of 5 minutes >140mmHg systolic, or > 80 mmHg, diastolic at screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment B+C: Obicetrapib + Drospirenone/Ethinyl Estradiol (COC)

    Obicetrapib 10 mg tablets and Drospirenone (3mg)/Ethinyl Estradiol (0.02mg) tablet

    Drug: Obicetrapib · Drug: Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)

  • Experimental
    Treatment B: Obicetrapib

    Obicetrapib 10 mg tablets (daily)

    Drug: Obicetrapib

  • Experimental
    Treatment C: Drospirenone/Ethinyl Estradiol tablets (COC)

    Drospirenone (3mg)/Ethinyl Estradiol tablets (0.02mg) tablet

    Drug: Drospirenone / Ethinyl Estradiol (COC)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of COC

    Plasma Cmax concentration of COC with and without Obicetrapib

    Time frame: Upon completion of Treatment C (Day -6) and Treatments B+C (Day 12)

  2. Area under the plasma concentration-time (AUC0-τ) curve for COC with and without coadministration with Obicetrapib

    Plasma AUC0-τ for COC with and without coadministration of Obicetrapib

    Time frame: Upon completion of Treatment C (Day -6) and Treatments B+C (Day 12)

07

Study locations

1 site
  • NOVUM
    Las Vegas, Nevada 89121, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Apr 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Feb 8, 2024
StartActual
Feb 5, 2024
Primary completionActual
Apr 25, 2024
CompletionActual
Apr 26, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06250205
Lead sponsor
NewAmsterdam Pharma
Collaborators
Novum
Responsible party
Sponsor
First posted
Feb 8, 2024
Start date
Feb 5, 2024
Primary completion
Apr 25, 2024
Completion
Apr 26, 2024
Last update
Sep 19, 2024

Study contacts

Kent A Swaine
principal investigator · Novum Pharmaceutical Research Services, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TA-8995 · Drospirenone · Ethinyl Estradiol

Start the discussion